Table 4.
Several metabolites mapped to PLS‐DA components one or two demonstrated significant (p < 0.05) associations with neutropenia based on the change in abundance between timepoints adjusted for baseline abundance (aOR change) or based on the baseline abundance (OR baseline).
| Metabolite | Metabolic pathway annotationa | PLS‐DA component | Component rankingb | OR (95% CI), baselinec | aOR (95% CI), changed |
|---|---|---|---|---|---|
| Citrulline | Urea cycle; Arginine and Proline Metabolism | 2 | 12 | 1.19 (0.61–2.30) | 0.08 (0.01–0.67) |
| 4‐ureidobutyrate | Pyrimidine Metabolism, Uracil containing | 1 | 2 | 1.59 (0.60–4.19) | 0.21 (0.05–0.77) |
| Fructose | Fructose, Mannose and Galactose Metabolism | 1 | 43 | 0.93 (0.79–1.09) | 2.47 (1.05–5.84) |
| N‐lactoyl phenylalanine | Lactoyl Amino Acid | 1 | 33 | 0.55 (0.19–1.56) | 3.89 (1.07–14.2) |
| Diacetylspermidine | Polyamine Metabolism | 1 | 32 | 1.46 (1.00–2.14) | 0.76 (0.47–1.24) |
| Alanylproline | Dipeptide | 1 | 8 | 2.35 (1.07–5.15) | 0.60 (0.24–1.50) |
| N6‐methyllysine | Lysine Metabolism | 1 | 3 | 3.10 (1.16–8.28) | 0.57 (0.22–1.50) |
| N‐palmitoyltaurine | Endocannabinoid | 1 | 34 | 3.40 (1.15–10.1) | 0.47 (0.12–1.91) |
| 3‐carboxy‐4‐methyl‐5‐pentyl‐2‐furanpropionate | Fatty Acid, Dicarboxylate | 1 | 26 | 3.47 (1.1–10.93) | 1.12 (0.67–1.87) |
| Phenylacetyltaurine | Acetylated Peptides | 1 | 22 | 12.8 (1.13–146.2) | 0.31 (0.03–3.29) |
| Ribitol | Pentose Metabolism | 1 | 38 | 0.37 (0.12–1.13) | 1.20 (0.69–2.08) |
| N‐acetyl‐1‐methylhistidine | Histidine Metabolism | 1 | 28 | 0.65 (0.18–2.41) | 0.43 (0.16–1.17) |
| Nicotinate | Nicotinate and Nicotinamide Metabolism | 1 | 30 | 1.36 (1.00–1.84) | 1.02 (0.75–1.38) |
| 4‐hydroxyphenylacetate | Phenylalanine Metabolism | 1 | 15 | 1.40 (0.78–2.52) | 0.17 (0.03–1.06) |
| N2‐acetyllysine | Lysine Metabolism | 2 | 16 | 1.45 (1.00–2.10) | 0.79 (0.49–1.27) |
| N‐acetyltaurine | Methionine, Cysteine, SAM and Taurine Metabolism | 1 | 37 | 1.48 (0.96–2.31) | 0.84 (0.61–1.17) |
| 3‐hydroxyvalerate | Fatty Acid, Monohydroxy | 2 | 29 | 1.57 (0.92–2.67) | 1.06 (0.52–2.14) |
| Pantothenate | Pantothenate and CoA Metabolism | 1 | 13 | 1.89 (0.98–3.63) | 0.74 (0.39–1.38) |
| Lactosyl‐N‐stearoyl‐sphingosine (d18:1/18:0) | Lactosylceramides | 1 | 47 | 2.54 (0.87–7.42) | 0.60 (0.22–1.59) |
| N6‐acetyllysine | Lysine Metabolism | 1 | 7 | 2.66 (0.86–8.21) | 0.84 (0.38–1.87) |
| N6‐carboxyethyllysine | Lysine Metabolism | 1 | 6 | 2.99 (0.96–9.33) | 0.83 (0.41–1.68) |
| Tyrosol | Tyrosine Metabolism | 1 | 9 | 3.10 (0.76–12.6) | 0.21 (0.04–1.12) |
| Beta‐sitosterol | Sterol | 1 | 45 | 3.44 (0.95–12.5) | 1.09 (0.40–2.98) |
| 2‐hydroxysebacate | Fatty Acid, Dicarboxylate | 1 | 18 | 4.51 (0.84–24.2) | 0.73 (0.29–1.81) |
Abbreviations: aOR, adjusted odds ratio; CI, confidence interval; PLS‐DA, partial least squares‐discriminant analysis; OR, odds ratio.
Per Metabolon.
From 1 (highest) to 50 (lowest), based on the absolute value of the loading score.
OR and 95% CI of neutropenia at the abx‐treated timepoint per one standard deviation increase in metabolite abundance at the baseline‐recovery timepoint (baseline).
OR and 95% CI of neutropenia at the abx‐treated timepoint per one standard deviation increase in metabolite abundance from the baseline‐recovery timpoint (baseline) to the abx‐treatment (follow‐up) timepoint. Adjusted for baseline metabolite abundance.